Systolic Global Longitudinal Strain: A Novel Predictor of Myocardial Fibrosis Extent in Patients with Hypertrophic Cardiomyopathy

Authors

  • Punchanit Wanichsetakul Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
  • Ing-orn Arunakul Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
  • Adisai Buakhamsri Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand

Keywords:

Hypertrophic cardiomyopathy, Myocardial fibrosis, Cardiac magnetic resonance (CMR) imaging, Global longitudinal strain

Abstract

Introduction: Myocardial fibrosis is a marker of adverse prognosis in hypertrophic cardiomyopathy (HCM). It can be assessed with cardiac magnetic resonance (CMR) using late gadolinium enhancement (LGE) as a gold standard. New echocardiographic parameters have ability to determine degree of myocardial fibrosis in patients with coronary heart disease. However, the relationship between these two imaging methods in identifying myocardial fibrosis in patient with HCM is still limited

Objectives: To evaluate the correlation of peak systolic global longitudinal strain (GLS) using 2D-speckle tracking echocardiogram (2D-STE) and the extent of LGE by CMR.

Methods: Adult patients with diagnosis of HCM at Thammasat University Hospital during January 2011 to December 2020 were identified if both comprehensive echocardiogram and CMR studies were performed less than 1 year apart. Standard echocardiographic parameters including GLS by 2D-STE were retrospectively measured. %LGE by CMR ≥15% was
defined as extensive LGE.

Results: Ninety-six patients with HCM were included (age = 67 ± 14, female 54%, GLS -14.2 ± 3.7%, extensive LGE 37.5%). GLS and maximal LV wall thickness were significantly correlated with %LGE in univariate analysis (r = 0.526, P ≤ .001 and r = 0.431, P ≤ .001, respectively). In multivariate linear regression analysis, both were independent predictors of %LGE (standard coefficient 0.418, P = .002 and standard coefficient 0.309, P = .017, respectively). GLS was an independent predictor of extensive LGE [(OR 1.2 (95% CI 1.04 - 1.46)), P = .013]. ROC analysis of GLS had demonstrated a best cutoff of -15% for prediction of extensive LGE (AUC of 0.68, sensitivity 74%, specificity 53%)

Conclusions: GLS was independently correlated with extent of LGE. 2D-STE strain analysis may be a potential tool for initial risk stratification in HCM.

Downloads

Download data is not yet available.

References

Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249-1254.

Harmon KG, Drezner JA, Maleszewski JJ, et al. Pathogeneses of sudden cardiac death in National Collegiate Athletic Association athletes. Circ Arrhythm Electrophysiol. 2014;7:198-204.

Correction to: 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2020;142.

Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC): The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733-2779.

Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2020;142:558-631.

O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-874.

Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the

evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130:484-495.

Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: A meta-analysis. JACC Cardiovasc Imaging. 2016;9:1392-1402.

Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370-377.

Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72:857-870.

Debonnaire P, Thijssen J, Leong DP, et al. Global longitudinal strain and left atrial volume index improve prediction of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging. 2014;30:549-558.

Haland TF, Almaas VM, Hasselberg NE, et al. Strain echocardiography is related to fibrosis and ventricular arrhythmias hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;17:613-621.

Candan O, Gecmen C, Bayam E, Guner A, Celik M, Dogan C. Mechanical dispersion and global longitudinal strain by speckle tracking echocardiography: Predictors of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy. Echocardiography. 2017;34:835-842.

Popovic ZB, Kwon DH, Mishra M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1299-1305.

Funabashi N, Takaoka H, Horie S, et al. Regional peak longitudinal-strain by 2D speckle-tracking TTE provides useful information to distinguish fibrotic from non-fibrotic lesions in LV myocardium on cardiac MR in hypertrophic cardiomyopathy. Int J Cardiol. 2013;168:4520-4523.

Hanvivadhanakul P, Buakhamsri A. Disease activity is associated with LV dysfunction in rheumatoid arthritis patients without clinical

cardiovascular disease. Adv Rheumatol. 2019;59:56.

Harrigan CJ, Peters DC, Gibson CM, et al. Hypertrophic cardiomyopathy: quantificatio of late gadolinium enhancement with contrastenhanced cardiovascular MR imaging. Radiology. 2011;258:128-133.

Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological

findings by CMR. JACC Cardiovasc Imaging. 2013;6:587-596.

Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28:183-193.

Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:17.

Chan RH, Maron BJ, Olivotto I, et al. Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2015;17:59.

Gommans DHF, Cramer GE, Fouraux MA, et al. Prediction of extensive myocardial fibrosis in nonhigh risk patients with hypertrophic

cardiomyopathy. Am J Cardiol. 2018;122:483-489.

Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552-563.

Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778-1785.

Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-424.

Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101:1406-1411.

Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1175-1181.

Richand V, Lafitte S, Reant P, et al. An ultrasound speckle tracking (two-dimensional strain) analysis of myocardial deformation in professional soccer players compared with healthy subjects and hypertrophic cardiomyopathy. Am J Cardiol. 2007;100:128-132.

Saito M, Okayama H, Yoshii T, et al. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13:617-623.

Hen Y, Iguchi N, Utanohara Y, et al. Extent of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese

hypertrophic cardiomyopathy patients. Circ J. 2016;80:950-957.

Downloads

Published

2023-04-27

How to Cite

[1]
Wanichsetakul, P., Arunakul, I.- orn . and Buakhamsri, A. 2023. Systolic Global Longitudinal Strain: A Novel Predictor of Myocardial Fibrosis Extent in Patients with Hypertrophic Cardiomyopathy. Asian Medical Journal and Alternative Medicine. 23, 1 (Apr. 2023), 59–68.

Issue

Section

Original Articles